A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience

被引：16

作者：

Saleh, Khalil ^{[1
]}

Danu, Alina ^{[1
]}

Koscielny, Serge ^{[2
]}

Legoupil, Clemence ^{[2
]}

Pilorge, Sylvain ^{[1
]}

Castilla-Llorente, Cristina ^{[1
]}

Ghez, David ^{[1
]}

Lazarovici, Julien ^{[1
]}

Michot, Jean-Marie ^{[1
]}

Khalife-Saleh, Nadine ^{[1
]}

Lapierre, Valerie ^{[1
]}

Alenxandrova, Kamelia ^{[2
]}

Arfi-Rouche, Julia ^{[3
]}

Bourhis, Jean-Henri ^{[1
]}

Ribrag, Vincent ^{[1
]}

机构：

[1] Gustave Roussy Canc Campus, Hematol Dept, Villejuif, France

[2] Gustave Roussy Canc Campus, Biostat Dept, Villejuif, France

[3] Gustave Roussy Canc Campus, Radiol Dept, Villejuif, France

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 11期

关键词：

Bendamustine; conditioning regimen; autologous stem cell transplantation; non-Hodgkin lymphoma; Hodgkin lymphoma; STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; NON-HODGKIN-LYMPHOMA; AUTOLOGOUS TRANSPLANTATION; OPEN-LABEL; PLUS RITUXIMAB; THERAPY; ETOPOSIDE; MELPHALAN;

D O I：

10.1080/10428194.2017.1403019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The combination of carmustine, etoposide, aracytin, and melphalan(BEAM) conditioning regimen in autologous stem-cell transplantation (ASCT) is widely used in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma. It is also an option in patients with very-high risk aggressive NHL in first complete remission (CR). Recently, a phase Ib-II feasibility study using bendamustine replacing carmustine (BCNU) was reported. We report herein a safety and efficacy analysis of bendamustine-EAM (BeEAM) with a control BEAM counterpart paired cohort (1/2). One hundred and two patients were analyzed. Overall survival (OS) and progression-free survival (PFS) were not reached and seemed to be comparable between both groups. However, grade III or greater diarrhea was significantly higher in BeEAM patients (44 vs. 15%, p = .002). The median number of days with fever >38 degrees C was significantly higher in BeEAM group (5.5 vs. 2, p < .001). This case-control study suggests that BeEAM followed by ASCT using bendamustine at 100 mg/m(2)/d is effective but has a different toxicity profile than the BEAM regimen.

引用

页码：2580 / 2587

页数：8

共 30 条

[1]

CHANTEPIE S, 2016, BLOOD, V128

[2] Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation [J].

Chen, Yi-Bin ;

Lane, Andrew A. ;

Logan, Brent R. ;

Zhu, Xiaochun ;

Akpek, Goerguen ;

Aljurf, Mahmoud. D. ;

Artz, Andrew S. ;

Bredeson, Christopher N. ;

Cooke, Kenneth R. ;

Ho, Vincent T. ;

Lazarus, Hillard M. ;

Olsson, Richard F. ;

Saber, Wael ;

McCarthy, Philip L. ;

Pasquini, Marcelo C. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (06) :1046-1053

[3] State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma [J].

Chiappella, Annalisa ;

Castellino, Alessia ;

Vitolo, Umberto .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (06) :1147-+

[4] First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial [J].

Eichhorst, Barbara ;

Fink, Anna-Maria ;

Bahlo, Jasmin ;

Busch, Raymonde ;

Kovacs, Gabor ;

Maurer, Christian ;

Lange, Elisabeth ;

Koeppler, Hubert ;

Kiehl, Michael ;

Soekler, Martin ;

Schlag, Rudolf ;

Vehling-Kaiser, Ursula ;

Koechling, Georg ;

Ploeger, Christoph ;

Gregor, Michael ;

Plesner, Torben ;

Trneny, Marek ;

Fischer, Kirsten ;

Doehner, Harmut ;

Kneba, Michael ;

Wendtner, Clemens-Martin ;

Klapper, Wolfram ;

Kreuzer, Karl-Anton ;

Stilgenbauer, Stephan ;

Boettcher, Sebastian ;

Hallek, Michael .

LANCET ONCOLOGY, 2016, 17 (07) :928-942

[5] Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies [J].

Gandhi, V .

SEMINARS IN ONCOLOGY, 2002, 29 (04) :4-11

[6] Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity [J].

Garciaz, S. ;

Coso, D. ;

de Collela, J-M Schiano ;

Broussais, F. ;

Stoppa, A-M ;

Aurran, T. ;

Chabannon, C. ;

Helvig, A. ;

Xerri, L. ;

Blaise, D. ;

Bouabdallah, R. .

BONE MARROW TRANSPLANTATION, 2016, 51 (02) :319-321

[7] High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma [J].

Gianni, AM ;

Bregni, M ;

Siena, S ;

Brambilla, C ;

DiNicola, M ;

Lombardi, F ;

Gandola, L ;

Tarella, C ;

Pileri, A ;

Ravagnani, F ;

Valagussa, P ;

Bonadonna, G ;

Stern, AC ;

Magni, M ;

Caracciolo, D .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (18) :1290-1297

[8] BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients [J].

Gilli, Stefanie ;

Novak, Urban ;

Taleghani, Behrouz Mansouri ;

Baerlocher, Gabriela M. ;

Leibundgut, Kurt ;

Banz, Yara ;

Zander, Thilo ;

Betticher, Daniel ;

Egger, Thomas ;

Rauch, Daniel ;

Pabst, Thomas .

ANNALS OF HEMATOLOGY, 2017, 96 (03) :421-429

[9] Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era [J].

Gisselbrecht, Christian ;

Glass, Bertram ;

Mounier, Nicolas ;

Gill, Devinder Singh ;

Linch, David C. ;

Trneny, Marek ;

Bosly, Andre ;

Ketterer, Nicolas ;

Shpilberg, Ofer ;

Hagberg, Hans ;

Ma, David ;

Briere, Josette ;

Moskowitz, Craig H. ;

Schmitz, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4184-4190

[10] Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study [J].

Hagberg, H ;

Gisselbrecht, C .

ANNALS OF ONCOLOGY, 2006, 17 :31-32

← 1 2 3 →